In this article, we will discuss Dostarlimab-gxly (Dosage Overview). So, let’s get started.
Dostarlimab-gxly is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer (EC), as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen.
Mismatch Repair Deficient (dMMR)Advanced Endometrial Cancer
Select patients with recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen for treatment with Dostarlimab-gxly based on the presence of dMMR in tumor specimens.
The recommended dosage of Dostarlimab-gxly is:
• Dose 1 through Dose 4: 500 mg every 3 weeks
• Subsequent dosing beginning 3 weeks after Dose 4 (Dose 5 onwards): 1,000 mg every
Administer Dostarlimab-gxly as an intravenous infusion over 30 minutes. Treat patients until disease progression or unacceptable toxicity.